209 related articles for article (PubMed ID: 10766342)
21. [Research on expression and control of p16 and p21 by wild-type p53 gene in two lung adenocarcinoma cell lines].
Jin Y; Yan CH; Wu Y; Liu Y; Zhang GY; Li P; Fu SB
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Oct; 20(5):409-12. PubMed ID: 14556194
[TBL] [Abstract][Full Text] [Related]
22. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
23. Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer.
Li X; Marani M; Yu J; Nan B; Roth JA; Kagawa S; Fang B; Denner L; Marcelli M
Cancer Res; 2001 Jan; 61(1):186-91. PubMed ID: 11196158
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer.
Modesitt SC; Ramirez P; Zu Z; Bodurka-Bevers D; Gershenson D; Wolf JK
Clin Cancer Res; 2001 Jun; 7(6):1765-72. PubMed ID: 11410518
[TBL] [Abstract][Full Text] [Related]
25. Sensitization of prostate cancer cell lines to 5-fluorocytosine induced by adenoviral vector carrying a CD transcription unit.
Yin L; Fu S; Wang X; Nanakorn T; Won J; Deisseroth A
Chin Med J (Engl); 2001 Sep; 114(9):972-5. PubMed ID: 11780394
[TBL] [Abstract][Full Text] [Related]
26. Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice.
Zhang YA; Nemunaitis J; Scanlon KJ; Tong AW
Gene Ther; 2000 Dec; 7(23):2041-50. PubMed ID: 11175317
[TBL] [Abstract][Full Text] [Related]
27. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
28. p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways.
Steiner MS; Wang Y; Zhang Y; Zhang X; Lu Y
Oncogene; 2000 Mar; 19(10):1297-306. PubMed ID: 10713671
[TBL] [Abstract][Full Text] [Related]
29. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
[TBL] [Abstract][Full Text] [Related]
30. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer.
Lee SJ; Zhang Y; Lee SD; Jung C; Li X; Kim HS; Bae KH; Jeng MH; Kao C; Gardner T
Mol Ther; 2004 Dec; 10(6):1051-8. PubMed ID: 15564137
[TBL] [Abstract][Full Text] [Related]
31. Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro.
Chintala SK; Fueyo J; Gomez-Manzano C; Venkaiah B; Bjerkvig R; Yung WK; Sawaya R; Kyritsis AP; Rao JS
Oncogene; 1997 Oct; 15(17):2049-57. PubMed ID: 9366522
[TBL] [Abstract][Full Text] [Related]
32. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression.
Rubinchik S; Wang D; Yu H; Fan F; Luo M; Norris JS; Dong JY
Mol Ther; 2001 Nov; 4(5):416-26. PubMed ID: 11708878
[TBL] [Abstract][Full Text] [Related]
33. [Exogenous mtsl/p16 gene suppresses tumorigenicity of human gastric cancer cell line].
Sun M; Lu Y
Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):410-3. PubMed ID: 10920869
[TBL] [Abstract][Full Text] [Related]
34. In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice.
Collinet P; Vereecque R; Sabban F; Vinatier D; Leblanc E; Narducci F; Querleu D; Quesnel B
J Obstet Gynaecol Res; 2006 Oct; 32(5):449-53. PubMed ID: 16984510
[TBL] [Abstract][Full Text] [Related]
35. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
36. Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study.
Kleinerman DI; Zhang WW; Lin SH; Nguyen TV; von Eschenbach AC; Hsieh JT
Cancer Res; 1995 Jul; 55(13):2831-6. PubMed ID: 7796410
[TBL] [Abstract][Full Text] [Related]
37. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
[TBL] [Abstract][Full Text] [Related]
38. Antitumor activity of the 16-kDa prolactin fragment in prostate cancer.
Kim J; Luo W; Chen DT; Earley K; Tunstead J; Yu-Lee LY; Lin SH
Cancer Res; 2003 Jan; 63(2):386-93. PubMed ID: 12543792
[TBL] [Abstract][Full Text] [Related]
39. Ovarian cancer G protein-coupled receptor 1, a new metastasis suppressor gene in prostate cancer.
Singh LS; Berk M; Oates R; Zhao Z; Tan H; Jiang Y; Zhou A; Kirmani K; Steinmetz R; Lindner D; Xu Y
J Natl Cancer Inst; 2007 Sep; 99(17):1313-27. PubMed ID: 17728215
[TBL] [Abstract][Full Text] [Related]
40. [Clinical application for gene therapy in prostate cancer].
Gotoh A; Kamidono S; Chung LW
Hinyokika Kiyo; 1997 Nov; 43(11):829-33. PubMed ID: 9436031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
